[11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors

EJNMMI Research

Volumn 3, Issue 1, 2013, Pages 1-11

  Buiter, Hans J C ^a   Windhorst, Albert D ^a   Huisman, Marc C ^a   Yaqub, Maqsood ^a   Knol, Dirk L ^a   Fisher, Abraham ^b   Lammertsma, Adriaan A ^a   Leysen, Josée E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Agonist; G protein coupled receptor; M1 muscarinic acetylcholine receptor; PET imaging; Rat brain

Indexed keywords

AF 150S; AF 150S C 11; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG RECEPTOR BINDING; DRUG UPTAKE; FRONTAL CORTEX; HIPPOCAMPUS; IN VIVO STUDY; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT;

EID: 84876900769     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-3-19     Document Type: Article

References (58)

1. Bartus RT: On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000, 163:495-529.
2. Caulfield MP: Muscarinic receptors - characterization, coupling and function. Pharmacol Ther 1993, 58:319-379.
3. Berstein G, Blank JL, Smrcka AV, Higashijima T, Sternweis PC, Exton JH, Ross EM: Reconstitution of agonist-stimulated phosphatidylinositol 4,5-bisphosphate hydrolysis using purified m1 muscarinic receptor, Gq/11, and phospholipase C-beta 1. J Biol Chem 1992, 267:8081-8088.
4. Mash DC, Potter LT: Autoradiographic localization of M1 and M2 muscarine receptors in the rat brain. Neuroscience 1986, 19:551-564.
5. Bymaster FP, Felder C, Ahmed S, McKinzie D: Muscarinic receptors as a target for drugs treating schizophrenia. Cur Drug Targets-CNS Neurol Disord 2002, 1:163-181.
6. Bymaster FP, Whitesitt CA, Shannon HE, DeLapp N, Ward JS, Calligaro DO, Shipley LA, BuelkeSam JL, Bodick NC, Farde L, Sheardown MJ, Olesen PH, Hansen KT, Suzdak PD, Swedberg MDB, Sauerberg P, Mitch CH: Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res 1997, 40:158-170.
7. Mirza NR, Peters D, Sparks RG: Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 2003, 9:159-186.
8. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM: Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997, 54:465-473.
9. Vora MM, Finn RD, Boothe TE, Liskwosky DR, Potter LT: [N-methyl-C-11]-scopolamine: synthesis and distribution in rat brain. J Labelled Comp Radiopharm 1983, 20:1229-1236.
10. 11C]N-methylpiperidyl benzilate ([11C]NMPB), a muscarinic acetylcholine receptor antagonist. Nuc Med Biol 1995, 22:13-17.
11. Dewey SL, Macgregor RR, Brodie JD, Bendriem B, King PT, Volkow ND, Schlyer DJ, Fowler JS, Wolf AP, Gatley SJ, Hitzemann R: Mapping muscarinic receptors in human and baboon brain using [N-C-11-methyl]-benztropine. Synapse 1990, 5:213-223.
12. 11C]quinuclidinyl benzilate and positron emission tomography in baboons. Eur J Pharmacol 1992, 213:275-284.
13. Zubieta JK, Koeppe AR, Frey KA, Kilbourn MR, Mangner TJ, Foster NL, Kuhl DE: Assessment of muscarinic receptor concentrations in affinity and Alzheimer disease with [C-11]NMPB and PET. Synapse 2001, 39:275-287.
14. McPherson W: Targeting cerebral muscarinic acetylcholine receptors with radioligands for diagnostic nuclear medicine studies. In Ion Channel Localization: Methods and Protocols. Edited by Lopatin AN, Nichols CG. Totowa (New York): Humana; 2001:17-38.
15. Christopoulos A, Kenakin T: G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002, 54:323-374.
16. Flynn DD, Mash DC: Distinct kinetic binding-properties of N-[H-3]-methylscopolamine afford differential labeling and localization of M1, M2, and M3-muscarinic receptor subtypes in primate brain. Synapse 1993, 14:283-296.
17. Potter LT, Ferrendelli CA, Hanchett HE: Two affinity states of M1 muscarine receptors. Cell Mol Neurobiol 1988, 8:181-191.
18. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P, Houle S, Kapur S, Wilson AA: Binding characteristics and sensitivity to endogenous dopamine of [C-11]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D-2 receptors in vivo using positron emission tomography. J Neurochem 2006, 97:1089-1103.
19. Finnema SJ, Seneca N, Farde L, Shchukin E, Sovago J, Gulyas B, Wikström HV, Innis RB, Neumeyer JL, Halldin C: A preliminary PET evaluation of the new dopamine D-2 receptor agonist [C-11]MNPA in cynomolgus monkey. Nuc Med Biol 2005, 32:353-360.
20. Mukherjee J, Narayanan TK, Christian BT, Shi BZ, Yang ZY: Binding characteristics of high-affinity dopamine D2/D3 receptor agonists, C-11 -PPHT and C-11-ZYY-339 in rodents and imaging in non-human primates by PET. Synapse 2004, 54:83-91.
21. Shi B, Narayanan TK, Christian BT, Chattopadhyay S, Mukherjee J: Synthesis and biological evaluation of the binding of dopamine D2/D3 receptor agonist, (R, S)-5-hydroxy-2-(N-propyl-N-(5'-18F-fluoropentyl)aminotetralin (18F-5-OH-FPPAT) in rodents and nonhuman primates. Nuc Med Biol 2004, 31:303-311.
22. 11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 2005, 48:4153-4160.
23. Frost JJ, Wagner HNJ, Dannals RF, Ravert HT, Links JM, Wilson AA, Burns HD, Wong DF, McPherson RW, Rosenbaum AE, Kuhar MJ, Snyder SH: Imaging opiate receptors in the human brain by positron tomography. J Comp Ass Tomogr 1985, 9:231-236.
24. Farde L, Suhara T, Halldin C, Nyback H, Nakashima Y, Swahn CG, Karlsson P, Ginovart N, Bymaster FP, Shannon HE, Foged C, Suzdak PD, Sauerberg P: PET study of the M(1)-agonists [C-11]xanomeline and [C-11]butylthio-TZTP in monkey and man. Dementia 1996, 7:187-195.
25. Fisher A, Heldman E, Gurwitz D, Haring R, Meshulam H, Brandeis R, Sapir M, Marciano D, Barak D, Vogel Z, Karton Y: AF150(S) and AF151(S): new M1 agonists mediate m1 selective signaling, neurotrophic-like effects and restore AF64A cognitive deficits in rats [abstract]. Soc Neurosci Abstr 1993, 19:1767.
26. Fisher A, Bar-Ner N, Karton Y: Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefore. 2003 (patent: WO 03/092580 A2).
27. Brandeis R, Sapir M, Hafif N, Abraham S, Oz N, Stein E, Fisher A: AF150(S): a new functionally selective M1 agonist improves cognitive performance in rats. Pharmacol Biochem Behav 1995, 51:667-674.
28. Beach TG, Walker DG, Potter PE, Sue LI, Fisher A: Reduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonists. Brain Res 2001, 905:220-223.
29. Fisher A, Brandeis R, Bar-Ner R, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z: AF150(S) and AF267B, M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci 2002, 19:145-153.
30. Fisher A: Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. J Neurochem 2012, 120:22-33.
31. Buiter HJC, Leysen JE, Schuit RC, Fisher A, Lammertsma AA, Windhorst AD: Radiosynthesis and biological evaluation of the M1 muscarinic acetylcholine receptor agonist ligand [11C]AF150(S). J Labelled Comp Radiopharm 2012, 55:264-273.
32. 18F-NaF deposition. J Nucl Med 2010, 51:1826-1829.
33. De Jong HWAM, van Velden FHP, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA: Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol 2007, 52:1505-1526.
34. Van Velden FHP, Kloet RW, van Berckel BNM, Lammertsma AA, Boellaard R: Accuracy of 3-dimensional reconstruction algorithms for the highresolution research tomograph. J Nucl Med 2009, 50:72-80.
35. Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MDB, Jeppesen L, Sheardown MJ, Sauerberg P, Fink-Jensen A: Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res 2000, 42:249-259.
36. 3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes. Life Sci 1983, 32:3001-3011.
37. Hudkins RL, DeHaven-Hudkins DL: M1 muscarinic antagonists interact with sigma recognition sites. Life Sci 1991, 49:1229-1235. Life Sci 1992, 50:245. Erratum.
38. Maruyama S, Tsukada H, Nishiyama S, Kakiuchi T, Fukumoto D, Oku N, Yamada S: In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. J Pharmacol Exp Ther 2008, 325:774-781.
39. 3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther 1982, 223:284-290.
40. Vannucchi MG, Scali C, Kopf SR, Pepeu G, Casamenti F: Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats. Neuroscience 1997, 79:837-846.
41. Wang RH, Bejar C, Weinstock M: Gender differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats. Neuropharmacology 2000, 39:497-506.
42. 18F]NaF scan and an MR based ROI template. Mol Imaging: Int J; 2012.
43. Bergstrom M, Grahnen A, Langstrom B: Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003, 59:357-366.
44. Lammertsma AA, Hume SP: Simplified reference tissue model for PET receptor studies. Neuroimage 1996, 4:153-158.
45. Jakubik J, Michal P, Machova E, Dolezal V: Importance and prospects for design of selective muscarinic agonists. Physiol Res 2008, 57:S39-S47.
46. Machova E, El-Fakahany EE, Dolezal V: Xanomeline quasi-irreversibly bound to an ectopic site can stimulate presynaptic M2 receptors via the orthosteric binding site. J Neurochem 2005, 94:90.
47. Oki T, Takagi Y, Inagaki S, Taketo MM, Manabe T, Matsui M, Yamada S: Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice. Mol Brain Res 2005, 133:6-11.
48. Tzavara ET, Bymaster FP, Felder CC, Wade M, Gomeza J, Wess J, McKinzie DL, Nomikos GG: Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2//M4 muscarinic receptor knockout mice. Mol Psychiatry 2003, 8:673-679.
49. Flynn DD, Reever CM, FerrariDiLeo G: Pharmacological strategies to selectively label and localize muscarinic receptor subtypes. Drug Dev Res 1997, 40:104-116.
50. Saller CF, Czupryna MJ, Salama AI: 5-Ht2 receptor blockade by Ici-169,369 and other 5-Ht2 antagonists modulates the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 1990, 253:1162-1170.
51. Damsma G, De Boer P, Westerink BHC, Fibiger HC: Dopaminergic regulation of striatal cholinergic interneurons: an in vivo microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 1990, 342:523-527.
52. DeBoer P, Abercrombie ED: Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes. J Pharmacol Exp Ther 1996, 277:775-783.
53. Billard W, Binch H, Crosby G, McQuade RD: Identification of the primary muscarinic autoreceptor subtype in rat striatum as M2 through a correlation of in vivo microdialysis and in vitro receptor binding data. J Pharmacol Exp Ther 1995, 273:273-279.
54. 11C]raclopride binding in rat striatum, quantified using PET. Synapse 1995, 21:45-53.
55. Hwang DR, Narendran R, Laruelle M: Positron-labeled dopamine agonists for probing the high affinity states of dopamine subtype 2 receptors. Bioconj Chem 2005, 16:27-31.
56. 11C]raclopride to measure amphetamine-induced dopamine release in the human striatum. J Pharmacol Exp Ther 2010, 333:533-539.
57. 11C]MNPA and antagonist [C-11]raclopride. Synapse 2006, 59:260-269.
58. Hall JM, Caulfield MP, Watson SP, Guard S: Receptor subtypes or species homologs - relevance to drug discovery. Trend Pharmacol Sci 1993, 14:376-383.